Search Results
Your search for ASCO matches 21172 pages
Showing 5851 - 5900Treating Colorectal Cancer in the Time of COVID-19
The treatment of colorectal cancer has always been something of an art—but never more so than during the COVID-19 pandemic. In the spring of 2020, The ASCO Post asked three experts in this malignancy to share their concerns and their approaches to achieving good patient outcomes while minimizing...
Adagrasib for Patients With Advanced KRAS G12C–Mutated NSCLC
Treatment with the KRAS G12C inhibitor adagrasib showed clinical activity in patients with advanced non–small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, confirming its role as a therapeutic target. Results from the KRYSTAL-1 trial were reported at the European Lung Cancer Virtual...
FDA Grants Two New Breakthrough Device Designations for Molecular Residual Disease Test
The U.S. Food and Drug Administration (FDA) granted two breakthrough device designations covering new intended uses of the Signatera molecular residual disease (MRD) test. These new designations will support the development of Signatera through phase III clinical trials as a companion diagnostic to ...
UC Davis Comprehensive Cancer Center Elected as NCCN Member Institution
The National Comprehensive Cancer Network® (NCCN®) announced that its board of directors has voted to elect the University of California (UC) Davis Comprehensive Cancer Center as its newest member institution. UC Davis joins 30 other leading academic cancer centers from across the United States...
Andreas Obermair, MD, on Treating Endometrial Adenocarcinoma With a Levonorgestrel Intrauterine Device
Andreas Obermair, MD, of the University of Queensland and Queensland Centre for Gynaecological Cancer Research, discusses data on a hormonal IUD used to treat women with the precursor lesion endometrial hyperplasia with atypia (EHA) and those with stage I endometrial adenocarcinoma (EAC). At 6...
Amir A. Jazaeri, MD, on Metastatic Cervical Cancer: The Role of Immunotherapy
Amir A. Jazaeri, MD, of The University of Texas MD Anderson Cancer Center, discusses data on the safety and efficacy of adoptive cell transfer using autologous tumor-infiltrating lymphocytes (LN-145) to treat patients with recurrent, metastatic, or persistent cervical carcinoma whose tumors have...
Eric Pujade-Lauraine, MD, PhD, on First-Line Maintenance Therapy in Ovarian Cancer
Eric Pujade-Lauraine, MD, PhD, of Hôpital Hôtel-Dieu, discusses results from the PAOLA-1ENGOT-ov25 trial on the use of homologous recombination–repair mutation gene panels and whether they can predict the efficacy of olaparib plus bevacizumab in first-line maintenance therapy for patients with...
Brittany A. Davidson, MD, on a Model to Predict the Need for Opioids After Gynecologic Surgery
Brittany A. Davidson, MD, of Duke University, discusses the development and validation of the GO-POP model (Gynecologic Oncology Predictor of Postoperative opioid use), an individualized patient-centered predictive tool designed to help avoid overprescribing pain medications (ID# 10253).
Dana M. Roque, MD, on Ovarian, Fallopian Tube, and Peritoneal Cancers: Possible New Therapeutic Option for Heavily Pretreated Disease
Dana M. Roque, MD, of the University of Maryland Medical Center, discusses phase II results showing that weekly ixabepilone plus biweekly bevacizumab may improve overall response rate as well as progression-free and overall survival for women with platinum-resistant or -refractory ovarian,...
Laura Chambers, DO, on Treating Epithelial Ovarian Cancer With Cisplatin and Paclitaxel During Surgery
Laura Chambers, DO, of the Cleveland Clinic, discusses data showing that combining paclitaxel and cisplatin vs cisplatin alone with hyperthermic intraperitoneal chemotherapy at interval debulking surgery improved progression-free survival. There was no difference in postoperative complications,...
I Want to Live Long and I Want to Live Well
I’m a person who doesn’t like uncertainty. I’m also a worrier. So, when my hand kept going to the same spot on the upper part of my left breast near my chest wall, I couldn’t shake the feeling that something wasn’t quite right, which persisted even after a routine mammography failed to find any...
ASTRO Recommendation on COVID-19 Vaccination for Patients Receiving Radiation Therapy
The American Society for Radiation Oncology (ASTRO) has compiled a selection of resources for radiation oncology professionals. The resources were developed by clinical teams and based on the best available information at the time they were posted. Physicians and their patients must make the...
Memorial Sloan Kettering Establishes Tow Center for Developmental Oncology
Memorial Sloan Kettering Cancer Center (MSK) recently announced the establishment of The Tow Center for Developmental Oncology (TCDO). The new institution will bring together the unique expertise of researchers and physicians from across MSK and empower them to pursue translational research...
Ravi Bellamkonda, PhD, Named Provost of Emory University
Emory University President Gregory L. Fenves, PhD, recently announced the appointment of biomedical scientist Ravi Bellamkonda, PhD, as the university’s next Provost and Executive Vice President for Academic Affairs, effective July 1, 2021. Dr. Bellamkonda returns to Emory after serving as Dean of...
Hans Clevers, MD, PhD, FAACR, Recognized With 2021 Pezcoller Foundation–AACR International Award
The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will be presented to Hans Clevers, MD, PhD, FAACR, at the virtual AACR Annual Meeting 2021, to be held April 10–15 and May 17–21. Dr. Clevers, who is...
Eleven Oncology Practices Receive Quality Certification From the Association for Clinical Oncology
The Association for Clinical Oncology congratulates the 11 practices that prioritized the quality of care they provide by achieving the Quality Oncology Practice Initiative (QOPI®) Certification in the second half of 2020. These practices have shown that they are committed to providing the...
Actions Early in Biden Administration Mirror ASCO Road to Recovery Report
ASCO’s Road to Recovery Report: Learning from the COVID-19 Experience to Improve Clinical Research and Cancer Care, among other recommendations, calls for the U.S. Department of Health and Human Services (HHS) to establish a special enrollment period on the federal health insurance exchange,...
Breast Cancer Susceptibility Genes: Putting the Pieces Together
With the widespread use of multigene panels for germline genetic testing, understanding the cancer risks associated with pathogenic or likely pathogenic variants (ie, mutations) has become increasingly necessary. To identify which genes are breast cancer susceptibility genes, population studies...
Oncology Clinician Well-Being Roadmap Provides 5-Year Plan to Address Provider Burnout
ASCO recently released the ASCO Oncology Clinician Well-Being Task Force Roadmap. The document outlines a 5-year plan to improve the quality of cancer care by enhancing the well-being of oncology clinicians and sustainability of oncology practices. The roadmap’s specific goals include promoting...
Health-Care Policy Expert Sybil R. Green, JD, RPh, MHA, Brings Wealth of Experience as ASCO’s First Diversity and Inclusion Officer
Sybil R. Green, JD, RPh, MHA, has been named Diversity and Inclusion Officer by ASCO. A health-care policy expert with experience in both corporate and nonprofit organizations, Ms. Green will guide ASCO’s internal and external initiatives aimed at achieving the Society’s equity, diversity, and...
Leading Health and Cancer Advocacy Groups Unite to Reduce Racial Disparities in Cancer Care
The National Comprehensive Cancer Network (NCCN), American Cancer Society Cancer Action Network (ACS CAN), and National Minority Quality Forum (NMQF) recently presented new ideas for overcoming inequality in oncology. The recommendations—developed by a group of 17 national experts, representing...
ASCO Publishes Guideline Endorsement of ASTRO Guideline for Radiation Therapy in SCLC
An ASCO Expert Panel has endorsed an American Society for Radiation Oncology (ASTRO) guideline on radiation therapy for small cell lung cancer (SCLC), stating the recommendations in the ASTRO guideline “are clear, thorough, and based upon the most relevant scientific evidence” available.1...
Challenges in Managing Hodgkin Lymphoma: Focus on Use of Brentuximab Vedotin
“I was taught that the way of progress was neither swift nor easy.” —Marie Curie To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are two abstracts selected from the meeting proceedings focusing on...
Female Breast Cancer Surpasses Lung Cancer as the Most Commonly Diagnosed Cancer Worldwide
Cancer ranks as a leading cause of death in every country in the world, and, for the first time, female breast cancer is the most commonly diagnosed cancer, overtaking lung cancer, according to a collaborative report from the American Cancer Society (ACS) and the International Agency for Research...
American Cancer Society Announces New Diversity in Cancer Research Program
The American Cancer Society recently launched the Diversity in Cancer Research program, a permanent umbrella that will support the American Cancer Society’s effort to foster a more diverse scientific workforce community. This has been made possible through an endowment contribution from Elizabeth...
Prevent Cancer Foundation Awards Nine New Research Grants
The Prevent Cancer Foundation has announced funding for nine scientists who are researching cancer prevention and early detection. Each scientist is being awarded $100,000 for 2 years. Areas of focus include the pancreas, esophagus, liver, lungs, skin, prostate, colon-rectum, and blood/bone ...
SGO and FWC Issue Joint Statement on the Elimination of HPV
United in their commitment to eliminate human papillomavirus (HPV)-related cancer, the Society of Gynecologic Oncology (SGO) and the Foundation for Women’s Cancer (FWC) recently endorsed a series of vaccine recommendations. HPV vaccines are among the most effective vaccines available worldwide,...
Sara Schottenstein Foundation, Dedicated to Gastric Cancer, Announces Launch
A science-focused organization dedicated to ending gastric cancer, the Sara Schottenstein Foundation recently announced its launch and its new website, http://www.saraschottensteinfoundation.org. Founded by Jeff Schottenstein, MBA, a wealth management professional in San Francisco, the Sara...
Sachin Apte, MD, MS, MBA, Joins Huntsman Cancer Institute as Chief Clinical Officer
Huntsman Cancer Institute (HCI) and University of Utah (U of U) Health announced the appointment of Sachin Apte, MD, MS, MBA, as Chief Clinical Officer of HCI and Physician-in-Chief of the cancer hospital. “Dr. Apte will lead HCI’s clinical efforts at a time when we are poised to dramatically...
Gynecologic Oncology Leader Named at New Jersey’s Only NCI-Designated Comprehensive Cancer Center
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital (RWJUH) have named James K. Aikins, Jr, MD, FACOG, FACS, Chief of Gynecologic Oncology at Rutgers Cancer Institute and Chief of Gynecologic Oncology Services at RWJUH. He will also serve as Program Director for the...
Patrick Delaney Named New Executive Director of NCCN Foundation
The National Comprehensive Cancer Network (NCCN) has announced the appointment of Patrick Delaney as incoming Executive Director for the NCCN Foundation. Mr. Delaney has previously held leadership roles with the Juvenile Diabetes Research Foundation, American Red Cross, and American Cancer Society. ...
Winthrop P. Rockefeller Cancer Institute Appoints New Deputy Director
Cancer researcher Alan Tackett, PhD, has been named Deputy Director of the Winthrop P. Rockefeller Cancer Institute (Cancer Institute) at the University of Arkansas for Medical Sciences (UAMS). Dr. Tackett, who is noted for his research in cancer biomarker discovery, is Professor in the UAMS...
Roswell Park, Bristol Myers Squibb Foundation Team Up to Fight Cancer in Native and Rural Communities
Roswell Park comprehensive Cancer Center and the Bristol Myers Squibb Foundation announced a $3.3 million program to address the cancer burden in rural areas and Native Nations across New York State, with an emphasis on the Western New York region. The grant from the Bristol Myers Squibb Foundation ...
Expert Point of View: Joshi J. Alumkal, MD
Invited discussant of the ACIS study, Joshi J. Alumkal, MD, leader of the Genitourinary Medical Oncology Section at the University of Michigan Rogel Cancer Center, noted that the toxicities were slightly higher with apalutamide plus abiraterone acetate/prednisone, including fatigue, hypertension,...
Adding Apalutamide to Abiraterone/Prednisone Extends Radiographic Progression-Free but Not Overall Survival
The phase III ACIS trial met its primary endpoint at 6 months showing that apalutamide plus abiraterone acetate/prednisone (AAP) extended radiographic progression-free survival vs abiraterone acetate/prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate...
Expert Point of View: Stephanie Berg, DO
Invited discussant of SWOG 1500, Stephanie Berg, DO, of Loyola University Chicago, was impressed by these results: “We should consider cabozantinib as another option for papillary renal cell carcinoma.” “Cabozantinib is a tyrosine kinase inhibitor with a broad range of targets, including MET, one...
SWOG 1500: Cabozantinib Extends Progression-Free Survival vs Sunitinib in Metastatic Papillary Renal Cell Carcinoma
Cabozantinib achieved a statistically significant and clinically meaningful extension in progression-free survival compared with sunitinib in patients with metastatic papillary renal cell carcinoma, a relatively uncommon type of renal cell carcinoma, according to the randomized phase II SWOG 1500...
Cancer Cell Therapy Pioneer Carl June, MD, Named 2021 Dan David Prize Laureate
International cancer cell therapy pioneer Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine and Director of the Center for Cellular Immunotherapies at Penn Medicine Abramson Cancer Center, has...
Expert Point of View: Richard K. Valicenti, MD
Invited discussant of the SAKK 09/10 trial, Richard K. Valicenti, MD, of the University of California, Davis, commented: “These results bring us closer to a more individualized approach than using PSA dynamics and conventional imaging. It does not appear that historic norms are sufficient to...
Comparing Radiotherapy Regimens for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
A dose-intensified approach to salvage radiotherapy failed to show superiority to a conventional-dose strategy in patients with biochemically recurrent prostate cancer who had undergone radical prostatectomy, according to the phase III SAKK 09/10 trial presented at the 2021 Genitourinary Cancers...
Expert Point of View: Oliver Sartor, MD
Oliver Sartor, MD, Assistant Dean for Oncology and Professor at the Tulane University School of Medicine, New Orleans, commended Dr. Hofman and colleagues for completing a randomized phase II trial of lutetium-177–labeled prostate-specific membrane antigen (PSMA-617), or LuPSMA, so quickly. He...
LuPSMA Outperforms Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer in Phase II Trial
Following disease progression on docetaxel, prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy reduced the risk of disease progression or death by 37% vs cabazitaxel in men with metastatic castration-resistant prostate cancer in the TheraP phase II trial reported at the 2021...
Expert Point of View: Arlene O. Siefker-Radtke, MD
“Now we know enfortumab vedotin-ejfv is here to stay in the armamentarium of treatment for advanced urothelial cancer,” said Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, during her discussion of both EV-301 and EV-201. “As we saw, overall survival was quite...
EV-301 and EV-201 Trials: Enfortumab Vedotin-ejfv Improves Survival in Metastatic Urothelial Cancer
Enfortumab vedotin-ejfv continues to move the needle forward as a validated treatment option for advanced urothelial carcinoma. At the 2021 Genitourinary Cancers Symposium, results from the phase III EV-301 study1 and EV-201 Cohort 22 provided support for the use of this agent in both patients...
Physician-Patient Relationship: Sacred and Sacrosanct
There are many relationships we build at work in our entire lifetime. Some are good, a few are not, and many are somewhere in between. But of all the relationships we are fortunate enough to build, there is no relationship more valuable and gratifying than the one between a physician and a ...
Development of Oral Taxane Tesetaxel to Be Discontinued
Following feedback from the U.S. Food and Drug Administration (FDA) in a pre–new drug application meeting, Odonate Therapeutics has concluded that the clinical data package for tesetaxel, an oral taxane tested in patients with metastatic breast cancer, is unlikely to support FDA approval....
Cardiovascular Risks Associated With Checkpoint Inhibitors and CAR T-Cell Therapy
In just a few years, immunotherapy has risen to become a pillar of cancer care, leading to significantly improved response rates and even cures in previously intractable diseases. Leveraging the immune system to treat cancer, however, also increases the potential for serious off-target effects....
Surgical Management of Melanoma With the Advent of Adjuvant Systemic Therapy
The results of a large cohort study suggest that a proportion of patients with cutaneous melanoma could potentially avoid sentinel node biopsy, according to data presented by Moncrieff et al at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care (Abstract 59)....
Rates of Seroconversion Among Patients With Cancer Infected With COVID-19
Most people with cancer who are infected with COVID-19 produce antibodies at a rate comparable to the rest of the population—but their ability to do so depends on the type of malignancy and the treatments they’ve received, according to a new study published by Thakkar et al in Nature Cancer. The...
Study Establishes Global Burden of Gallbladder and Biliary Tract Cancer
Although cancers of the gallbladder or bile ducts are rare, their rates of occurrence are increasing. A recent study published by Ouyang et al in the journal Cancer provided details on the burden of gallbladder and biliary tract cancer across 195 countries and territories from 1990 to 2017....
